

References

I-293

1. Lymphir™ (denileukin diftitox-cxdl) for injection, for intravenous use [package insert]. Citius Pharmaceuticals, Inc. Cranford, NJ. Revised 08/2024.
2. Clinical Pharmacology™ Compendium. 2024. Tampa FL: Gold Standard, Inc. Denileukin diftitox
3. Micromedex DrugDex Compendium®. 2024. Denileukin diftitox-cxdl.
4. National Comprehensive Cancer Network (NCCN). Lymphir. NCCN Drugs and Biologics Compendium®. 2024.
5. Foss F M, Kim Y H, Prince M H, et al. Efficacy and safety of E7777 (improved purity denileukin diftitox [ONTAK]) in patients with relapsed or refractory cutaneous T-cell lymphoma: results from pivotal study 302. *Blood*. 2022;140(1): 1491–1492.